{"entity":{"id":"nct05877430","kind":"trial","name":"Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in melanoma and metastatic cancer, run by CJ Bioscience, Inc., now recruiting.","summary":"Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer is a phase 1/2 interventional study registered as NCT05877430 by CJ Bioscience, Inc., with 160 participants planned, started 2023-09-11 and due to reach its primary completion in 2026-07. Interventions recorded: CJRB-101, Pembrolizumab injection. Conditions listed: NSCLC, HNSCC, Melanoma, Metastatic Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05877430","url":"https://clinicaltrials.gov/study/NCT05877430"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","metastatic-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05877430-j-immunother-cancer-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05877430","phase":"1/2","setting":"Phase 1/2 Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer","sponsor":"CJ Bioscience, Inc.","started":"2023-09-11","startedType":"actual","enrolled":160,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05877430/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"paper":[{"id":"paper-nct05877430-j-immunother-cancer-2026","kind":"paper","name":"Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma","route":"/key-papers/paper-nct05877430-j-immunother-cancer-2026/"}]}}